How much revenue does Junshi BIO make?

Junshi BIO reported 1.95 billion CNY in revenue for fiscal year 2024, up 29.7% from 1.50 billion CNY in fiscal year 2023.

Where does Junshi BIO make most of its revenue?

China: 92% of revenue by region in fiscal year 2025, followed by Overseas (8%).

What companies are similar to Junshi BIO?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Jiangsu Hengrui Medicine Co., Ltd. (600276.SS), Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS), Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS), Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS).

Junshi BIO (688180.SS) Stock

About Junshi BIO

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phas...

At a glance

Junshi BIO reported revenue of 1.95 billion CNY for fiscal year 2024, up 29.7% from fiscal year 2023, and net income of -1.28 billion CNY. China was its largest region in fiscal year 2025, with 92% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.